Siga Technologies (NASDAQ:SIGA) Releases Quarterly Earnings Results

Siga Technologies (NASDAQ:SIGA) issued its quarterly earnings results on Thursday. The company reported ($0.05) earnings per share for the quarter, FiscalAI reports. The business had revenue of $6.24 million for the quarter. Siga Technologies had a net margin of 24.61% and a return on equity of 11.25%.

Here are the key takeaways from Siga Technologies’ conference call:

• SIGA expects approximately $13 million of oral TPOXX deliveries to an international customer in Q2 plus additional IV TPOXX shipments to the U.S. SNS, which should materially boost near-term product revenue versus Q1.
• The company reported a strong balance sheet with about $146 million in cash and no debt at March 31, 2026, and paid a $0.60 special cash dividend while stating pro forma cash would remain above $100 million.
• The CHMP recommended withdrawing the mpox indication in Europe (while reaffirming smallpox, cowpox and vaccinia), which could limit EU label-based use and potential demand beyond core smallpox stockpiling.
• SIGA entered an exclusive licensing and distribution agreement with Hikma for the MENA region, with SIGA as the exclusive finished-product supplier, positioning the company to access underrepresented markets (financial terms confidential).
• Pipeline progress includes a filed IND and initiated Phase I pediatric study with results expected in H2 2026, and targeting an FDA submission for a post-exposure prophylaxis (PEP) indication within the next 12 months, representing regulatory catalysts.

Siga Technologies Trading Up 1.5%

NASDAQ SIGA traded up $0.07 on Friday, reaching $4.80. The stock had a trading volume of 1,079,699 shares, compared to its average volume of 566,908. Siga Technologies has a 1 year low of $4.29 and a 1 year high of $9.62. The business has a 50 day moving average price of $5.13 and a 200 day moving average price of $6.15. The company has a market capitalization of $344.26 million, a price-to-earnings ratio of 15.48 and a beta of 0.93.

Siga Technologies Dividend Announcement

The company also recently disclosed a special dividend, which was paid on Thursday, April 23rd. Investors of record on Tuesday, April 7th were given a dividend of $0.60 per share. The ex-dividend date of this dividend was Tuesday, April 7th.

Analyst Ratings Changes

Separately, Weiss Ratings lowered Siga Technologies from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, April 10th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Sell”.

Institutional Investors Weigh In On Siga Technologies

Several large investors have recently made changes to their positions in the company. CSM Advisors LLC raised its holdings in shares of Siga Technologies by 66.5% during the 3rd quarter. CSM Advisors LLC now owns 596,512 shares of the company’s stock valued at $5,458,000 after purchasing an additional 238,255 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in Siga Technologies by 744.6% during the third quarter. JPMorgan Chase & Co. now owns 211,055 shares of the company’s stock valued at $1,931,000 after acquiring an additional 186,067 shares during the period. WINTON GROUP Ltd bought a new stake in Siga Technologies during the 3rd quarter valued at approximately $966,000. Principal Financial Group Inc. grew its stake in shares of Siga Technologies by 36.3% in the third quarter. Principal Financial Group Inc. now owns 43,993 shares of the company’s stock worth $403,000 after acquiring an additional 11,717 shares during the last quarter. Finally, LSV Asset Management grew its position in Siga Technologies by 9.8% in the 3rd quarter. LSV Asset Management now owns 418,330 shares of the company’s stock worth $3,828,000 after purchasing an additional 37,342 shares during the last quarter. Institutional investors own 55.40% of the company’s stock.

Siga Technologies Company Profile

Siga Technologies, Inc (NASDAQ: SIGA) is a specialty pharmaceutical company focused on the development, manufacturing and commercialization of medical countermeasures for public health emergencies and biological threats. The company’s flagship product, TPOXX® (tecovirimat), is the first and only antiviral approved by the U.S. Food and Drug Administration for the treatment of smallpox. Siga has entered into procurement and development contracts with U.S. government agencies, including the Biomedical Advanced Research and Development Authority (BARDA) and the Department of Defense, to supply TPOXX® for the Strategic National Stockpile.

Founded in 2002, Siga has built a pipeline of therapies targeting high-consequence pathogens such as smallpox, plague and other potential biothreat agents.